Bruker Corporation - BRKR STOCK NEWS

Bruker Corporation (Nasdaq: BRKR) announced a quarterly cash dividend of $0.05 per share, payable on September 16, 2022, to shareholders of record as of September 1, 2022. This dividend reflects the company's commitment to returning value to its investors. Bruker is dedicated to enabling scientific breakthroughs and innovative applications across various sectors, including life sciences and diagnostics, enhancing productivity and customer success. For additional details, visit www.bruker.com.

Bruker Corporation (Nasdaq: BRKR) reported Q2 2022 revenues of $588.4 million, up 3.1% year-over-year, with organic growth of 8.8%. GAAP diluted EPS was $0.33, down from $0.38 in Q2 2021, while non-GAAP diluted EPS rose 2.3% to $0.45. For FY 2022, the company maintains its organic revenue growth guidance of 7% to 9%, despite adjusting reported revenue growth expectations to 2.5% to 4.5% due to currency headwinds. Non-GAAP operating margin is projected to expand by 30 to 60 basis points, with EPS expected between $2.29 and $2.33, marking a 9% to 11% increase year-over-year.

Bruker Corporation (Nasdaq: BRKR) will announce its second quarter 2022 financial results on August 3, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern Time to discuss results and business trends. Investors can participate via webcast on Bruker's website or by telephone. Pre-registration is available to expedite entry. A replay of the call will be accessible from one hour after its conclusion until September 3, 2022. Bruker specializes in high-performance scientific instruments and solutions to enhance research and diagnostics.

Acuamark Diagnostics announced the closing of an $11.3 million Series A funding round led by Claudio Del Vecchio and joined by Bruker Corporation. The funds will further develop AcuamarkDx's technology for early cancer detection, aiming for more reliable and cost-effective solutions. Del Vecchio joins the board, bringing extensive experience from Luxottica and Brooks Brothers. The company plans to scale sample collections and enhance its infrastructure to optimize clinical assessments.

Bruker Corporation has received three new orders for its Ascend Evo 1.0 GHz NMR magnets, designed for structural biology and clinical research in single-story laboratories. These orders are from the RIKEN Center for Biosystems Dynamics Research in Japan, and research centers in Spain. The Ascend Evo 1.0 GHz offers enhanced sensitivity, reduced helium consumption by 65%, and a smaller footprint, making advanced research accessible. Additionally, Bruker introduced the Heliosmart Recovery system for efficient helium recovery.

Bruker Corporation (Nasdaq: BRKR) has launched PhenoRisk PACS™ RuO, a research-use-only NMR test for analyzing blood samples from Long COVID patients. Developed in collaboration with the Australian National Phenome Center, this innovative test identifies early-stage risk factors and monitors recovery through a 20-minute assessment of biological markers. It aims to enhance understanding of Long COVID's impact on various organs, potentially aiding clinical research and treatment. The test offers significant advancements in the assessment of metabolic and proteomic biomarkers linked to SARS-CoV-2.

Bruker Corporation (Nasdaq: BRKR) revealed significant innovations in spatial multiomics at the 18th International Conference of the Metabolomics Society. Key advancements include Spatial Single-Cell Metabolomics (SSCM) for detailed metabolic tissue characterization and a new microGRID™ technology enhancing the timsTOF® fleX system's capabilities. These tools enable high-resolution metabolic analyses essential for cancer research and drug discovery. Additionally, Bruker launched updated MetaboScape and TASQ software for enhanced metabolomic profiling.

Bruker Corporation (NASDAQ: BRKR) showcased its innovative scientific instruments and solutions at Analytica 2022, emphasizing advancements in materials and energy research, as well as biopharmaceuticals. Notable product launches include the HYPERION II FT-IR microscope, TGA II FT-IR module, and DART-EVOQ mass spectrometry system, enhancing analytical capabilities across industries. The introduction of Spatial Single-Cell Metabolomics signifies a leap in cancer research and cell biology. These innovations aim to improve laboratory efficiency and analytical precision for a range of applications.

Bruker Corporation (Nasdaq: BRKR) has launched the NeuraLight 3D Ultra module, enhancing its Ultima multiphoton microscopes for advanced neuroscience and optogenetics research. This module features 3D holographic photostimulation, a larger liquid crystal chip for improved targeting, and a speed of 600 hologram frames per second. It allows researchers to study neural networks more effectively. The NeuraLight 3D Ultra is compatible with newer and selected older Ultima models, promoting innovation in neuroscience research.